Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40194 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL22199369 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL19228952 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL19228957 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL19228949 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL10089720 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL10138522 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL935503 | 0.95 | — | — | |
| SCHEMBL26205670 | 0.90 | TSHR (0.47) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL22589673 | 0.86 | TSHR (0.48) | TSHRMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230287030-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-10188136-B2 | Hydrophobin mimics: process for preparation thereof | INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IN) | 2019-01-29 | — | — | US | disclosed |
| US-20170362266-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION | 2017-12-21 | — | — | US | disclosed |
| US-20170231260-A1 | HYDROPHOBIN MIMICS: PROCESS FOR PREPARATION THEREOF | INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IN) | 2017-08-17 | — | — | US | disclosed |
| US-20170231260-A1 | HYDROPHOBIN MIMICS: PROCESS FOR PREPARATION THEREOF | INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IN) | 2017-08-17 | — | — | US | disclosed |
| US-20120046461-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | NORTHEASTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | TSHR 2184/4885MEN1 3968/4885KMT2A 4104/4885 |
| US-20170231260-A1 | HYDROPHOBIN MIMICS: PROCESS FOR PREPARATION THEREOF | CHN2, NEFM, HGF | TSHR 4020/4885MEN1 317/4885KMT2A 4097/4885 |
| US-20120046461-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | ESRRA, ESRRB, NR5A1 | TSHR 1263/4885MEN1 4158/4885KMT2A 3900/4885 |
| US-20170362266-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | TSHR 3743/4885MEN1 4631/4885KMT2A 3703/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | TSHR 2184/4885MEN1 3968/4885KMT2A 4104/4885 |
| US-20230287030-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | TSHR 3743/4885MEN1 4631/4885KMT2A 3703/4885 |
| US-10188136-B2 | Hydrophobin mimics: process for preparation thereof | CHN2, NEFM, HGF | TSHR 4020/4885MEN1 317/4885KMT2A 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.